OR WAIT null SECS
April 10, 2015
Aptar Pharma has partnered with Shanghai Sine Promod Pharmaceutical to develop and launch its new budesonide dry powder inhaler (DPI), which features Aptar Pharma’s user-friendly and cost-effective Twister DPI.
April 07, 2015
Theravectys has been granted authorization by the French National Agency for Medicines and Health Product Safety to produce lentiviral vectors for Phase I to Phase III testing at its manufacturing plant.
Novartis will make payments to Juno to settle a patent dispute covering chimeric antigen receptor T-cell (CAR-T) therapies.
March 18, 2015
WuXi's new facility in Philadelphia will manufacture CAR T-cell therapies and other cancer immunotherapies.
February 23, 2015
Leased facilities in California will expand Kite Pharma's capacity for clinical T-cell therapies.
February 19, 2015
The Berlin-Buch facility will begin manufacture of the company’s immune cell therapy.
February 12, 2015
Genzyme will partner with Voyager Therapeutics for the discovery, development, and commercialization of novel gene therapies for central nervous system disorders.
January 29, 2015
AstraZeneca and the University of Texas MD Anderson Cancer Center announced a plan to collaborate for the improvement of patient outcomes in clinical trials with investigational therapies.
January 22, 2015
Syncona and Kite Pharma announced separate investments into T-cell therapies to fight cancerous tumors.
January 13, 2015
Boehringer Ingelheim announced that it would collaborate with Yale University to research novel therapeutic targets in immune-modulation.